Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Change in Accured Expenses (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Change in Accured Expenses for 9 consecutive years, with -$6.4 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Change in Accured Expenses fell 281.99% year-over-year to -$6.4 million, compared with a TTM value of -$5.8 million through Jun 2025, down 245.59%, and an annual FY2025 reading of -$12.3 million, down 304.74% over the prior year.
  • Change in Accured Expenses was -$6.4 million for Q2 2025 at VYNE Therapeutics, down from -$2.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.5 million in Q2 2024 and bottomed at -$9.6 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is -$822166.7, with a median of -$217500.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses plummeted 4782.93% in 2022, then soared 1072.73% in 2024.
  • Year by year, Change in Accured Expenses stood at -$2.8 million in 2021, then surged by 188.71% to $2.5 million in 2022, then plummeted by 60.61% to $993000.0 in 2023, then surged by 121.55% to $2.2 million in 2024, then plummeted by 391.18% to -$6.4 million in 2025.
  • Business Quant data shows Change in Accured Expenses for VYNE at -$6.4 million in Q2 2025, -$2.5 million in Q1 2025, and $2.2 million in Q4 2024.